Archive · 16 Dec 2025
Glenmark Licenses NSCLC Drug to Hansoh Pharma
Glenmark Pharmaceuticals has made a deal with Hansoh Pharma.
They will develop and sell a drug called Aumolertinib in many countries.
These countries include places in the Middle East, Africa, Asia, Australia, and more.
The drug is for a type of lung cancer.
Glenmark's stock price went down a little after this news.
This means they will work together to bring this medicine to people in these areas.
Glenmark Pharmaceuticals has signed an exclusive licensing agreement with Hansoh Pharma for the drug Aumolertinib.
The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in specified territories.
Licensed territories include the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and selected Caribbean countries.
Glenmark's stock price ended at ₹1,962.00, down by ₹23.60 or 1.19% on the BSE.
Aumolertinib is intended for the treatment of non-small cell lung cancer (NSCLC).
- Who
- Glenmark Pharmaceuticals and Hansoh Pharma
- What
- Exclusive licensing agreement for Aumolertinib
- When
- Not specified
- Where
- Licensed territories include Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and selected Caribbean countries
- Why
- To develop and commercialize Aumolertinib in the licensed territories
- Company
- Glenmark Pharmaceuticals
- Drug
- Aumolertinib
- Licensed Territories
- Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and selected Caribbean countries
- Stock Price Change
- ₹1,962.00, down by ₹23.60 (1.19%)
- Exchange
- BSE